I was very disappointed to find your June issue published with a sticker advertising a webinar for bioidentical hormones and to find an additional full-page advertisement at the back of the Journal after the text. The featured experts include directors of the Bioidentical Hormone Institute, whose website contains opinion pieces and professional blogs but appears to lack a peer review process. The May 31, 2010, issue of the Medical Letter on Drugs and Therapeutics , which is one of the most respected impartial sources for pharmacologic efficacy and safety data, was quite clear in stating that there are no established advantages of such hormonal preparations vs existing commercially produced plant-based estrogen replacement therapy. The risks, benefits, and side-effects would also be the same. I believe this perspective is valuable for your Journal readers.